|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.38 USD | -0.29% |
|
+0.21% | -8.80% |
| 04-16 | Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026 | CI |
| 04-15 | Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says | MT |
Evolution of the Average Target: AbbVie Inc.
Evolution of the Target Price: AbbVie Inc.
Changes in Analyst Recommendations: AbbVie Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +19.49% | |||||
| +30.51% | |||||
| +7.22% | |||||
| +7.52% | |||||
| +9.02% | |||||
| +1.1% | |||||
| -0.92% | |||||
| +18.15% | |||||
| +15.05% | |||||
| Average | +11.91% | |||||
| Weighted average by Cap. | +14.84% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Evercore ISI | |
| Guggenheim | |
| Cantor Fitzgerald | |
| Daiwa Securities | |
| Piper Sandler | |
| HSBC | |
| BNP Paribas | |
| Goldman Sachs | |
| Morgan Stanley | |
| UBS | |
| Citigroup | |
| Berenberg Bank | |
| Leerink Partners | |
| Rothschild & Co Redburn | |
| Wolfe Research | |
| Argus | |
| Scotiabank | |
| Bernstein | |
| BNP Paribas Exane | |
| Raymond James | |
| JPMorgan Chase | |
| BMO Capital | |
| TD Cowen | |
| Deutsche Bank Securities | |
| Wells Fargo Securities | |
| DBS Bank | |
| Ameriprise Financial | |
| Redburn Atlantic | |
| Truist Securities | |
| Barclays | |
| Mizuho Securities | |
| Morningstar | |
| William Blair & Co. | |
| BofA Securities | |
| Atlantic Equities | |
| SVB Securities LLC | |
| Credit Suisse | |
| Societe Generale | |
| Cowen | |
| Redburn | |
| SVB Leerink | |
| RBC Capital Markets |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
- Consensus AbbVie Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition